{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:09:55Z","timestamp":1788318595494,"version":"build-2803163510"},"reference-count":45,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s303052","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T21:10:15Z","timestamp":1647033015000},"page":"223-232","source":"Crossref","is-referenced-by-count":24,"title":["Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus"],"prefix":"10.2147","volume":"Volume 18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9442-0396","authenticated-orcid":true,"given":"Ronak G","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7320-2234","authenticated-orcid":true,"given":"Camille N","family":"Kotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12006","volume":"13","author":"Kotton","year":"2013","journal-title":"Am J Transplant"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/cid\/ciy696","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab988","author":"Avery","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0166-3542(02)00094-3","volume":"56","author":"Evers","year":"2002","journal-title":"Antiviral Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11899-020-00557-6","volume":"15","author":"Hakki","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.antiviral.2018.07.013","volume":"157","author":"Chou","year":"2018","journal-title":"Antiviral Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-385987-7.00004-X","volume":"80","author":"Marschall","year":"2011","journal-title":"Adv Virus Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/rmv.615","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev Med Virol"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Aoki FY.\u00a0Antivirals against herpes viruses. In: Bennett JE, Dolin R, Blaser MJ editor(s).\u00a0Prinicples and Practice of Infectious Diseases. Elsevier,\u00a02015;8(1):546\u201062.","DOI":"10.1016\/B978-1-4557-4801-3.00045-X"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1128\/AAC.46.9.2969-2976.2002","volume":"46","author":"Lalezari","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1128\/AAC.47.4.1334-1342.2003","volume":"47","author":"Wang","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.coviro.2011.10.011","volume":"1","author":"Marty","year":"2011","journal-title":"Curr Opin Virol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","volume":"12","author":"Winston","year":"2012","journal-title":"Am J Transplant"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1399-3062.2010.00550.x","volume":"12","author":"Avery","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/cid\/ciy706","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref22","unstructured":"Duarte R, Alain S, Chemaly R, et al. TMaribavir Versus Investigator-Assigned Therapy for the Treatment of Transplant Recipients With Refractory\/Resistant Cytomegalovirus Infection: efficacy Data From a Randomized Phase 3 Open-Label Study 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT). 2021."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Pereira M, Cervera C, Kotton C Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: phase 3 Trial Results presented at IDWeek; September 29-October 3, 2021; Virutal Abstract; 2021.","DOI":"10.1093\/ofid\/ofab466.021"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"12108","DOI":"10.1128\/JVI.01575-09","volume":"83","author":"Wang","year":"2009","journal-title":"J Virol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1128\/AAC.00951-07","volume":"52","author":"Goldwater","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1111\/j.1600-6143.2009.02768.x","volume":"9","author":"Pescovitz","year":"2009","journal-title":"Am J Transplant"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"S370","DOI":"10.1016\/j.bbmt.2018.12.600","volume":"25","author":"Song","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/jcph.1504","volume":"60","author":"Song","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"ref29","unstructured":"Song IH, Ilic K, Wu J Lack of drug\u2013drug interaction between maribavir and voriconazole. Poster presented at: American Transplant Congress (ATC) Meeting May 30, 2020. Poster A-176; 2020."},{"key":"ref30","unstructured":"Chetty M, Neuhoff S, Barter Z, Maribavir dose considerations for treatment of cytomegalovirus infections during co-administration of CYP3A4 inducers and inhibitors, based on physiologically based pharmacokinetic modeling. Poster presented at. Eleventh American Conference on Pharmacometrics (ACoP11).November 9-13, 2020. Poster TUE-035; 2020."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1128\/JVI.01787-07","volume":"82","author":"Chou","year":"2008","journal-title":"J Virol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1086\/518514","volume":"196","author":"Chou","year":"2007","journal-title":"J Infect Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1128\/JVI.78.13.7124-7130.2004","volume":"78","author":"Chou","year":"2004","journal-title":"J Virol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"104616","DOI":"10.1016\/j.antiviral.2019.104616","volume":"172","author":"Chou","year":"2019","journal-title":"Antiviral Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa462","author":"Chou","year":"2020","journal-title":"J Infect Dis"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/rmv.574","volume":"18","author":"Chou","year":"2008","journal-title":"Rev Med Virol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"11499","DOI":"10.1128\/JVI.77.21.11499-11506.2003","volume":"77","author":"Komazin","year":"2003","journal-title":"J Virol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","volume":"37","author":"Drew","year":"2006","journal-title":"J Clin Virol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1086\/653122","volume":"202","author":"Strasfeld","year":"2010","journal-title":"J Infect Dis"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","volume":"163","author":"Piret","year":"2019","journal-title":"Antiviral Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/cid\/ciy585","volume":"67","author":"Chung","year":"2018","journal-title":"Clin Infect Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2018.8431","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"ref43","unstructured":"Takeda Pharmaceuticals. Livtencity (Maribavir) [Package Insert]. Lexington, MA: Takeda Pharmaceuticals; 2021."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/AAC.02337-18","volume":"63","author":"Turner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/jpids\/pit048","volume":"2","author":"Upadhyayula","year":"2013","journal-title":"J Pediatric Infect Dis Soc"}],"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=79054","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=79054","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T21:10:19Z","timestamp":1647033019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/evaluating-the-safety-of-maribavir-for-the-treatment-of-cytomegaloviru-peer-reviewed-fulltext-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":45,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s303052","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}